Seven phase I-II studies fell within the inclusion criteria.
Details on the radiotherapy technique, patient selection, fractionation scheme, exclusion criteria, treatment toxicity, quality-of-life, and tumor control were collected. The studies provide encouraging results of acute and late toxicity, with rare grade 3 events, that seem comparable to robotic SBRT. The biochemical disease-free survival rates look promising, but most patients belong to the low-risk group. The trials are limited by a short follow-up, small number of patients, and different approaches in prescribing dose and defining the acceptable dose heterogeneities. Currently, nonrobotic SBRT regimens should be used in the context of clinical trials.
Written by:
Macias VA, Perez-Romasanta LA. Are you the author?
Department of Radiation Oncology, Salamanca University Hospital, Salamanca, Spain.
Reference: Cancer Invest. 2014 Mar 21. Epub ahead of print.
doi: 10.3109/07357907.2014.896015
PubMed Abstract
PMID: 24654695
UroToday.com Prostate Cancer Section
